Overview
- The collaboration will evaluate the safety and effectiveness of influenza, COVID-19 and RSV vaccines ahead of the 2026–2027 respiratory virus season.
- Outputs will be public evidence reviews to inform clinical care and state policy, not federal vaccine recommendations.
- The process features public protocols, systematic literature reviews, comparative analyses, monthly expert meetings, conflict-of-interest disclosures and philanthropic funding.
- The AMA and Vaccine Integrity Project say ACIP’s system has effectively collapsed, while HHS rejects that claim and maintains ACIP remains the national advisory body.
- The move follows federal changes to vaccine guidance that prompted divergence by states and medical societies, alongside polling that shows trust in the CDC has fallen to 47%.